BMP-9 compositions

• US 6,034,061 A
• Filed: 12/04/1996
• Issued: 03/07/2000
• Est. Priority Date: 06/25/1991
• Status: Expired due to Fees

• Current Assignee: Genetics Institute LLC (Pfizer Inc.)
• Original Assignee: Genetics Institute LLC (Pfizer Inc.)
• Inventors: Rosen, Vicki A., Thies, Scott R., Wozney, John M., Celeste, Anthony J., Song, Jeffrey R.
• Primary Examiner(s): Kemmerer, Elizabeth C
• Assistant Examiner(s): Romeo, David S.
• Application Number:
  US08/750,222
• Time in Patent Office: 1,189 Days
• Field of Search: 530/399, 530/840, 930/120, 514/2, 514/12, 424/423, 424/426, 435/69.4, 435/240.2, 536/24.31, 536/23.51
• US Class Current: 514/8.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: Y10S 530/84 Bones; tendons; teeth; cartilage
• CPC Class Codes: Y10S 930/12 Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Abstract

Purified Bone Morphogenetic Protein (BMP)-9 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair, and in hepatic growth and function.

Claims

1. A method for inducing formation of chondrocyte tissue in a patient in need of same comprising the step of administering to said patient an effective amount of a BMP-9 protein said protein comprising an amino acid sequence selected from the group consisting of:

(a) amino acids 1 or 8 through 110 of SEQ ID NO;

9; and

(b) amino acids 319 or 326 through 428 of SEQ ID NO;

2 effective to induce the formation of chondrocyte tissue in said patient.

2. A method for inducing formation of cartilage tissue in a patient in need of same comprising the step of administering to said patient an effective amount of a BMP-9 protein said protein comprising an amino acid sequence selected from the group consisting of:

amino acids 1 or 8 through 110 of SEQ ID NO;

9; and

b) amino acids 319 or 326 through 428 of SEQ ID NO;

2 effective to induce the formation of cartilage tissue in said patient.

3. A method for inducing bone formation in a patient in need of same comprising the step of administering to said patient an effective amount of a BMP-9 protein said protein comprising an amino acid sequence selected from the group consisting of:

(a) amino acids 1 or 8 through 110 of SEQ ID NO;

9; and

(b) amino acids 319 or 326 through 428 of SEQ ID NO;

2 effective to induce the formation of bone in said patient.

4. A method for increasing hepatocyte proliferation in a patient in need of same comprising the step of administering to said patient an effective amount of a BMP-9 polypeptide protein said protein comprising an amino acid sequence selected from the group consisting of:

(a) amino acids 1 or 8 through 110 of SEQ ID NO;

9; and

(b) amino acids 319 or 326 through 428 of SEQ ID NO;

2 effective to increase hepatocyte proliferation in said patient.